These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 25431270)

  • 1. Cystic fibrosis bone disease: is the CFTR corrector C18 an option for therapy?
    Velard F; Delion M; Lemaire F; Tabary O; Guillaume C; Le Pimpec Barthès F; Touqui L; Gangloff S; Sermet-Gaudelus I; Jacquot J
    Eur Respir J; 2015 Mar; 45(3):845-8. PubMed ID: 25431270
    [No Abstract]   [Full Text] [Related]  

  • 2. Cystic fibrosis-related bone disease.
    Paccou J; Fardellone P; Cortet B
    Curr Opin Pulm Med; 2013 Nov; 19(6):681-6. PubMed ID: 24060979
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The F508del mutation in cystic fibrosis transmembrane conductance regulator gene impacts bone formation.
    Le Henaff C; Gimenez A; Haÿ E; Marty C; Marie P; Jacquot J
    Am J Pathol; 2012 May; 180(5):2068-75. PubMed ID: 22449949
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correctors of the basic trafficking defect of the mutant F508del-CFTR that causes cystic fibrosis.
    Birault V; Solari R; Hanrahan J; Thomas DY
    Curr Opin Chem Biol; 2013 Jun; 17(3):353-60. PubMed ID: 23711435
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Severe osteopenia in CFTR-null mice.
    Dif F; Marty C; Baudoin C; de Vernejoul MC; Levi G
    Bone; 2004 Sep; 35(3):595-603. PubMed ID: 15336594
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The challenges of developing effective anti-inflammatory agents in cystic fibrosis.
    Sagel SD
    J Cyst Fibros; 2015 Mar; 14(2):164-6. PubMed ID: 25576392
    [No Abstract]   [Full Text] [Related]  

  • 7. Novel pharmacological strategies to treat cystic fibrosis.
    Hanrahan JW; Sampson HM; Thomas DY
    Trends Pharmacol Sci; 2013 Feb; 34(2):119-25. PubMed ID: 23380248
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rescue of functional CFTR channels in cystic fibrosis: a dramatic multivalent effect using iminosugar cluster-based correctors.
    Compain P; Decroocq C; Joosten A; de Sousa J; Rodríguez-Lucena D; Butters TD; Bertrand J; Clément R; Boinot C; Becq F; Norez C
    Chembiochem; 2013 Oct; 14(15):2050-8. PubMed ID: 24038832
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug bests cystic-fibrosis mutation.
    Ledford H
    Nature; 2012 Feb; 482(7384):145. PubMed ID: 22318583
    [No Abstract]   [Full Text] [Related]  

  • 10. Cystic fibrosis and bone disease: defective osteoblast maturation with the F508del mutation in cystic fibrosis transmembrane conductance regulator.
    Velard F; Delion M; Le Henaff C; Guillaume C; Gangloff S; Jacquot J; Tabary O; Touqui L; Barthes F; Sermet-Gaudelus I
    Am J Respir Crit Care Med; 2014 Mar; 189(6):746-8. PubMed ID: 24628315
    [No Abstract]   [Full Text] [Related]  

  • 11. Genetics of cystic fibrosis: CFTR mutation classifications toward genotype-based CF therapies.
    Fanen P; Wohlhuter-Haddad A; Hinzpeter A
    Int J Biochem Cell Biol; 2014 Jul; 52():94-102. PubMed ID: 24631642
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Acute recurrent pancreatitis and heterozygous mutation of the cystic fibrosis gene: a case report].
    Vodoff MV; Gilbert B; Piguet C; Sautereau D; de Lumley L
    Arch Pediatr; 2000 Apr; 7(4):388-90. PubMed ID: 10793926
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cystic fibrosis: experience in one institution.
    Liu LC; Shyur SD; Chu SH; Huang LH; Kao YH; Lei WT; Cheng CH; Lo CY; Chen CK; Fang LC
    J Microbiol Immunol Infect; 2014 Aug; 47(4):358-61. PubMed ID: 22992393
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of the cystic fibrosis mutation F508del-CFTR on renal cyst formation and growth.
    Li H; Yang W; Mendes F; Amaral MD; Sheppard DN
    Am J Physiol Renal Physiol; 2012 Oct; 303(8):F1176-86. PubMed ID: 22874761
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Modifier genes and cystic fibrosis].
    Corvol H; Flamant C; Vallet C; Clement A; Brouard J
    Arch Pediatr; 2006 Jan; 13(1):57-63. PubMed ID: 16274977
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cystic fibrosis transmembrane conductance regulator (CFTR)-mediated residual chloride secretion does not protect against early chronic Pseudomonas aeruginosa infection in F508del homozygous cystic fibrosis patients.
    Derichs N; Mekus F; Bronsveld I; Bijman J; Veeze HJ; von der Hardt H; Tummler B; Ballmann M
    Pediatr Res; 2004 Jan; 55(1):69-75. PubMed ID: 14605249
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cystic fibrosis transmembrane conductance regulator-mRNA delivery: a novel alternative for cystic fibrosis gene therapy.
    Bangel-Ruland N; Tomczak K; Fernández Fernández E; Leier G; Leciejewski B; Rudolph C; Rosenecker J; Weber WM
    J Gene Med; 2013; 15(11-12):414-26. PubMed ID: 24123772
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cystic fibrosis transmembrane conductance regulator channel dysfunction in non-cystic fibrosis bronchiectasis.
    Bienvenu T; Sermet-Gaudelus I; Burgel PR; Hubert D; Crestani B; Bassinet L; Dusser D; Fajac I
    Am J Respir Crit Care Med; 2010 May; 181(10):1078-84. PubMed ID: 20167849
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Cystic fibrosis transmembrane conductance regulator (CFTR) gene: mutations and clinical phenotypes].
    Schwartz M
    Ugeskr Laeger; 2003 Feb; 165(9):912-6. PubMed ID: 12661515
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The cystic fibrosis V232D mutation inhibits CFTR maturation by disrupting a hydrophobic pocket rather than formation of aberrant interhelical hydrogen bonds.
    Loo TW; Clarke DM
    Biochem Pharmacol; 2014 Mar; 88(1):46-57. PubMed ID: 24412276
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.